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A BS TR AC T
BACKGROUND
Supplementation with antioxidant vitamins has been proposed to reduce the risk of 
preeclampsia and perinatal complications, but the effects of this intervention are 
uncertain.
METHODS
We conducted a multicenter, randomized trial of nulliparous women between 14 
and 22 weeks of gestation. Women were assigned to daily supplementation with 
1000 mg of vitamin C and 400 IU of vitamin E or placebo (microcrystalline cellu-
lose) until delivery. Primary outcomes were the risks of maternal preeclampsia, 
death or serious outcomes in the infants (on the basis of definitions used by the 
Australian and New Zealand Neonatal Network), and delivering an infant whose 
birth weight was below the 10th percentile for gestational age.
RESULTS
Of the 1877 women enrolled in the study, 935 were randomly assigned to the vita-
min group and 942 to the placebo group. Baseline characteristics of the two groups 
were similar. There were no significant differences between the vitamin and placebo 
groups in the risk of preeclampsia (6.0 percent and 5.0 percent, respectively; relative 
risk, 1.20; 95 percent confidence interval, 0.82 to 1.75), death or serious outcomes 
in the infant (9.5 percent and 12.1 percent; relative risk, 0.79; 95 percent confidence 
interval, 0.61 to 1.02), or having an infant with a birth weight below the 10th per-
centile for gestational age (8.7 percent and 9.9 percent; relative risk, 0.87; 95 percent 
confidence interval, 0.66 to 1.16).
CONCLUSIONS
Supplementation with vitamins C and E during pregnancy does not reduce the risk 
of preeclampsia in nulliparous women, the risk of intrauterine growth restriction, or 
the risk of death or other serious outcomes in their infants. (Controlledtrials.com 
number, ISRCTN00416244.)
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Preeclampsia is a multisystem disor-der characterized by hypertension and pro-teinuria occurring in the second half of 
pregnancy.1 Nulliparity is a recognized risk factor. 
Preeclampsia carries risks of serious complica-
tions and death for the mother.1-3 For the infant, 
risks include death, preterm birth, intrauterine hy-
poxia, and poor intrauterine growth.1,4,5
The pathogenesis of preeclampsia involves in-
adequate trophoblast invasion,6 often leading to 
poor placental perfusion; generalized endothelial 
dysfunction7; and immune maladaptation and in-
flammation.8 Oxidative stress, characterized by 
excessive production of reactive oxygen species, 
coupled with inadequate or overwhelmed anti-
oxidant defense mechanisms, has been proposed 
as a link between these events.
Antioxidants are important in maintaining 
cellular integrity in a normal pregnancy by inhib-
iting peroxidation reactions and thus protecting 
enzymes, proteins, and cells from destruction by 
peroxides. Antioxidant defense mechanisms in-
clude cellular and extracellular enzymes such as 
glutathione reductase, superoxide dismutase, cata-
lase, and free-radical scavengers, including vita-
mins C and E, carotenoids, glutathione, serum 
albumin, and metabolites such as bilirubin and 
uric acid. Vitamins C and E are antioxidants de-
rived from the diet. Vitamin C scavenges free 
radicals in the aqueous phase, and the lipid-solu-
ble vitamin E acts in vivo to prevent the forma-
tion of lipid peroxides and thus protect cell mem-
branes.
There is evidence of oxidative stress in women 
with established preeclampsia, including increased 
plasma concentrations of 8-epi-prostaglandin 
F
2α
,9 lipid peroxides,10 and decreased concentra-
tions of antioxidants such as vitamins C and E.11 
Oxidative stress is implicated in complications 
affecting preterm infants, including the respira-
tory distress syndrome, chronic lung disease, in-
traventricular hemorrhage, retinopathy of prema-
turity, and necrotizing enterocolitis.12,13 These 
observations led to the premise that prophylaxis 
with antioxidants may prevent oxidative stress 
and thereby reduce the risk of both preeclampsia 
in pregnant women and perinatal complications 
in their infants.
An initial randomized trial of prophylactic 
supplementation with antioxidants provided dur-
ing pregnancy to 283 women at risk for preeclamp-
sia, as compared with women not receiving an-
tioxidant supplementation, showed a significant 
reduction in preeclampsia (8 percent vs. 17 per-
cent) and a nonsignificant reduction in the risk 
of the infant’s being small for gestational age.14 
However, a subsequent trial of antioxidants in 
109 women reported no significant reduction in 
the risk of preeclampsia (17 percent, vs. 19 per-
cent in the placebo group).15 There is limited in-
formation about the effects of antioxidants on 
serious health outcomes in infants and on wheth-
er there may be benefits independent of a reduc-
tion in preeclampsia. There have been calls for 
further randomized trials in populations that 
have a different risk of preeclampsia to assess the 
efficacy and safety of antioxidant supplementa-
tion.1,14,15
We designed the Australian Collaborative Trial 
of Supplements (ACTS) with vitamin C and vita-
min E to assess whether supplementation reduced 
perinatal complications in nulliparous women 
and their infants, including preeclampsia, death, 
or serious outcomes, and small size for gesta-
tional age.
Me thods
STUDY DESIGN AND POPULATION
We conducted a multicenter, randomized trial in-
volving nulliparous women with a singleton preg-
nancy between 14 and 22 weeks of gestation. 
Eligible women had normal blood pressure at the 
first measurement in pregnancy and again at trial 
entry. Women with any of the following were in-
eligible: known multiple pregnancy, known poten-
tially lethal fetal anomaly, known thrombophilia, 
chronic renal failure, antihypertensive therapy, 
or specific contraindications to vitamin C or E 
therapy such as hemochromatosis or anticoagu-
lant therapy.16
The protocol was approved by the research and 
ethics committees at the nine collaborating hos-
pitals. All women provided written informed 
consent.
INTERVENTION
The treatment packs contained four sealed, 
opaque, white plastic bottles of either the anti-
oxidants vitamin C and vitamin E or the placebo 
and were prepared by a researcher not involved 
in recruitment or clinical care. Stratification was 
according to collaborating center and gestational 
age (less than 18 weeks vs. 18 weeks or more). 
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Randomization was performed through a central 
telephone randomization service. Women assigned 
to the vitamin group were advised to take four 
coated tablets of a combination of 250 mg of vita-
min C (as ascorbic acid) and 100 IU of vitamin E 
(as d-alpha-tocopherol succinate) each day from 
trial entry until they gave birth. The total daily 
dose of vitamin C was 1000 mg, and that of vita-
min E, 400 IU. Women assigned to placebo were 
advised to take four tablets daily containing micro-
crystalline cellulose, which were similarly coated 
and identical in appearance to the vitamin tablets.
Women were asked to swallow the tablets 
whole without crushing or chewing them and 
were advised to take two tablets in the morning 
and two tablets in the evening. They were advised 
not to take any other antioxidant supplements, 
although a multivitamin preparation that provid-
ed a daily intake of no more than 200 mg of 
vitamin C or 50 IU of vitamin E was permitted. 
All infants in the study were recommended to 
receive intramuscular vitamin K after birth.16
The care that the women and their infants 
received was according to standard practice at 
each center, with surveillance for hypertension 
with the use of standardized measurements of 
blood pressure.17 Korotkoff phase V was used to 
measure diastolic blood pressure unless the dia-
stolic blood pressure was 0 mm Hg, in which 
case Korotkoff phase IV was used. If the wom-
an’s blood pressure was elevated, urinalysis for 
proteinuria was recommended.
The women completed a food-frequency ques-
tionnaire at trial entry to assess dietary intake.18 
Adherence to and the side effects of treatment 
were assessed by self-completed questionnaires 
that the women answered postnatally. Women 
were specifically asked how often they missed 
taking the trial tablets and how many times a 
week they missed taking all the tablets. Adher-
ence was defined by consumption of at least 80 
percent of all tablets at recommended times.
OUTCOME VARIABLES
There were three primary outcomes: the develop-
ment of preeclampsia in the mother, a composite 
measure of death or serious outcomes in the in-
fant, and the birth of an infant who was small for 
gestational age. Preeclampsia was defined as hy-
pertension (systolic blood pressure ≥140 mm Hg 
or diastolic blood pressure [Korotkoff V] ≥90 
mm Hg on at least two occasions four or more 
hours apart, or both) arising after 20 weeks’ ges-
tation and one or more of the following: protein-
uria, renal insufficiency, liver disease, neurologic 
problems, hematologic disturbances, or fetal-
growth restriction17 (Table 1). The composite mea-
sure of serious outcomes in the infant was defined 
as one or more of the following: fetal death after 
trial entry (categorized as either before 20 weeks’ 
gestation, or at 20 weeks’ gestation or later); death 
of a live-born infant before hospital discharge; 
birth weight below the 3rd percentile for gesta-
tional age; severe respiratory distress syndrome 
(defined by a mean airway pressure of ≥10 mm Hg 
or a fraction of inspired oxygen of ≥0.80 cm of 
water, or both); chronic lung disease; intraven-
tricular hemorrhage of grade 3 or 4; cystic peri-
ventricular leukomalacia; retinopathy of prema-
turity of stage 3 or 4; necrotizing enterocolitis; 
Apgar score of less than 4 at 5 minutes; seizures 
before 24 hours of age or requiring two or more 
drugs to control; hypotonia for at least 2 hours; 
stupor; decreased response to pain; coma; tube 
feeding for 4 or more days; care in the neonatal 
intensive care unit for more than 4 days; or use of 
ventilation for 24 hours or more. These definitions 
of serious outcomes are based on those used by 
the Australian and New Zealand Neonatal Net-
work19 and are important measures of morbidity 
at or beyond term.20 Small size for gestational 
age was defined by a birth weight below the 10th 
percentile for gestation according to fetal sex on 
standardized birth-weight charts.21
Secondary outcomes in the infants included 
serious complications occurring before hospital 
discharge. For the women, secondary outcomes 
included a composite of any of the following until 
six weeks post partum: death, pulmonary edema, 
eclampsia, stroke, thrombocytopenia, renal insuf-
ficiency, respiratory distress syndrome, cardiac 
arrest, respiratory arrest, placental abruption, ab-
normal liver function, preterm prelabor rupture 
of membranes, major postpartum hemorrhage, 
postpartum pyrexia, pneumonia, deep-vein throm-
bosis, or pulmonary embolus requiring antico-
agulant therapy. Other outcomes included ante-
natal, intrapartum, and postnatal end points, 
particularly those related to hypertensive disease, 
including the need for antenatal hospitalization 
or antenatal care during the day for hypertension, 
need for induction of labor for hypertension, use 
of antihypertensive agents, and use of magne-
sium sulfate.
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STATISTICAL ANALYSIS
Analyses were performed on an intention-to-treat 
basis with the use of SAS software, version 9.1. 
No adjustments were made, since prognostic fac-
tors were balanced at trial entry between the two 
groups. Relative risks with 95 percent confidence 
intervals are used for dichotomous variables. Con-
tinuous variables, if normally distributed, were 
analyzed with the use of Student’s t-test, and non-
parametric tests were used for skewed data. For 
the small number of twins (four pairs) in the study, 
outcomes for one randomly selected infant in 
each pair of twins were included in the analyses. 
A P value of less than 0.05 was considered to in-
dicate statistical significance. All P values were 
two-sided. A step-down Sidak adjustment was 
made for the analyses involving multiple primary 
end points, with adjusted P values reported.22
We estimated that a sample size of 1870 wom-
en would have a statistical power of 80 percent 
(two-tailed alpha level of 0.05) to detect a reduc-
tion in the risk of death or serious outcomes in 
the infants from 6.5 percent to 3.7 percent23 (and 
Clinical Information Services at the Women’s and 
Children’s Hospital, Adelaide). Although our trial 
was powered to focus on the serious outcomes 
for the infant, we estimated that this sample size 
would also have a statistical power of 80 percent 
to detect a reduction in the risk of preeclampsia 
among the women from 10.0 percent to 6.3 per-
cent. An interim analysis was not performed. The 
treatment allocation was broken after the analy-
ses were completed. The suppliers of the tablets 
were not involved in any other aspect of the study 
including design, data management, or prepara-
tion of the manuscript.
R esult s
Of the 1877 women enrolled, 935 (49.8 percent) 
were assigned to the vitamin group and 942 (50.2 
percent) to the placebo group (Fig. 1). Recruit-
ment started in December 2001 and was com-
pleted in January 2005. Clinical outcomes were 
available up until hospital discharge for all the 
women who underwent randomization and their 
infants.
At study entry, maternal baseline characteris-
tics in the two groups were similar, including 
median dietary intake of vitamins C and E (Ta-







(95% CI)* P Value†
number (percent)
Women
Preeclampsia‡ 56 (6.0) 47 (5.0) 1.20 (0.82–1.75) 0.57
Infants
Death or serious outcome 89 (9.5) 114 (12.1) 0.79 (0.61–1.02) 0.20
Small for gestational age§ 80 (8.7) 92 (9.9) 0.87 (0.66–1.16) 0.57
* CI denotes confidence interval (unadjusted).
† P values were adjusted for multiple comparisons.
‡ Preeclampsia was defined as hypertension occurring with one or more of the following: proteinuria, defined as ≥300 mg 
of protein per 24 hours or a ratio of protein to creatinine of ≥30 mg per millimole in a “spot” urine specimen; renal in-
sufficiency, defined by a serum or plasma creatinine level ≥0.09 mmol per liter (≥1.02 mg per deciliter) or oliguria (<30 ml 
of urine per hour for ≥6 hours); liver disease, defined by an aspartate aminotransferase or alanine aminotransferase level 
of >50 IU per liter, severe epigastric or right-upper-quadrant pain, or both; neurologic problems, defined as convulsions 
(eclampsia); hyperreflexia with clonus; severe headaches with hyperreflexia or persistent visual disturbances (scotomata); 
hematologic disturbances (thrombocytopenia, defined by a platelet count of <100,000 per cubic millimeter; disseminated 
intravascular coagulation, defined by an international normalized ratio of >1.5, an activated partial-thromboplastin time 
>5 seconds longer than the laboratory reference value, or a fibrinogen level of <1 g per liter; hemolysis, defined by a lac-
tate dehydrogenase level >500 IU per liter, fragmentocytes on peripheral-blood smear, or both); or fetal growth restric-
tion, defined by a birth weight below the 10th percentile for gestational age. The number of women with hypertension 
and one or more of the following abnormalities were as follows: proteinuria, 4.7 percent in the vitamin group and 2.8 
percent in the placebo group; renal insufficiency, 1.0 percent and 0.3 percent, respectively; liver disease, 2.4 percent and 
0.6 percent; neurologic problems, 1.8 percent and 1.8 percent; hematologic disturbances, 0.6 percent and 0.1 percent; 
and fetal growth restriction, 0.9 percent and 1.2 percent.
§ The analysis included 924 live-born infants in the vitamin group and 929 live-born infants in the placebo group.
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ble 2). There was no significant difference in es-
timated adherence between the vitamin group 
and the placebo group (66.6 percent vs. 69.9 per-
cent; relative risk, 0.95; 95 percent confidence 
interval, 0.89 to 1.02).
PRIMARY OUTCOMES
There were no significant differences between the 
vitamin group and the placebo group in the risk 
of preeclampsia (6.0 percent and 5.0 percent, re-
spectively; relative risk, 1.20; 95 percent confi-
dence interval, 0.82 to 1.75), the risk of death or 
serious outcomes in the infants (9.5 percent and 
12.1 percent; relative risk, 0.79; 95 percent confi-
dence interval, 0.61 to 1.02), or the risk of hav-
ing an infant who was small for gestational age 
(8.7 percent and 9.9 percent; relative risk, 0.87; 
95 percent confidence interval, 0.66 to 1.16) 
(Table 1).
SECONDARY OUTCOMES
When the individual outcomes included in the 
composite end point of death or serious outcomes 
in the infants were examined, there were no sig-
nificant differences for any of the outcomes be-
tween the two groups (Table 3). The rate of pre-
term birth was similar in the two groups (Table 4). 
As compared with infants in the placebo group, 
significantly fewer of those in the vitamin group 
had the respiratory distress syndrome (0.2 percent 
vs. 1.3 percent; relative risk, 0.17; 95 percent con-
fidence interval, 0.04 to 0.75) and fewer required 
surfactant (0.2 percent vs. 1.0 percent; relative 
risk, 0.22; 95 percent confidence interval, 0.05 to 
1.03) (Table 4). There was no significant differ-
ence between the two groups of infants in the 
need for mechanical ventilation or the risk of 
other adverse outcomes, including measures of 
growth (Table 4).
942 (50.2%) Assigned 
to placebo
935 (49.8%) Assigned 
to vitamins C and E
942 (100%) Had pregnancy-outcome data
929 (98.6%) Live births
7 (0.7%) Early fetal deaths at <20 wk
6 (0.6%) Stillbirths at ≥20 wk
935 (100%) Had pregnancy-outcome data
924 (98.8%) Live births
3 (0.3%) Early fetal deaths at <20 wk
8 (0.9%) Stillbirths at ≥20 wk
1877 Eligible women underwent
randomization
569 (60.9%) <18 Wk
of gestation
366 (39.1%) ≥18 Wk
of gestation
568 (60.3%) <18 Wk
of gestation
374 (39.7%) ≥18 Wk
of gestation
942 Women and their infants
included in primary analyses
935 Women and their infants
included in primary analyses
Figure 1. Disposition of Women and Their Infants in the Trial.
Live births included one neonate in the vitamin group (0.1 percent) and four in the placebo group (0.4 percent) who 
died before hospital discharge.
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The risk of death or serious outcomes did not 
differ significantly between the women in the 
vitamin group and those in the placebo group 
(10.1 percent vs. 7.7 percent; relative risk, 1.30; 
95 percent confidence interval, 0.97 to 1.74) 
(Table 5). No significant differences were seen 
between the groups for any of the individual 
components of the composite maternal end point 
apart from a higher frequency of abnormal re-
sults on liver-function tests (raised aminotrans-
ferase levels) in the vitamin group; testing was 
performed only in the subgroup of women con-
sidered to have clinical indications for testing.
Women in the vitamin group had an increased 
risk of being admitted antenatally for hyperten-
sion and being prescribed antihypertensive drugs 
(Table 4). There were no significant differences 
between the two groups in the timing of detec-






Age — yr 26.3±5.6 26.6±5.8
Gestational age — wk 17.1±2.3 17.1±2.3





Interquartile range 21.3–27.7 21.7–27.5
Previous pregnancies lasting <20 wk — no. (%) 269 (28.8) 278 (29.5)
Race or ethnic group — no. (%)‡
White 891 (95.3) 886 (94.1)
Asian 27 (2.9) 32 (3.4)
Other 17 (1.8) 24 (2.5)
Smoker — no. (%)† 210 (22.5) 195 (20.7)
Level of education — no. (%)
Secondary or lower 435 (46.5) 424 (45.0)
Postsecondary training program 215 (23.0) 229 (24.3)
University studies 285 (30.5) 289 (30.7)
Adequate dietary intake of vitamin C§
Intake of vitamin C — no./total no. (%) 777/831 (93.5) 772/834 (92.6)
Median — mg 201.8 208.9
Interquartile range — mg 137.1–309.2 134.9–317.0
Adequate dietary intake of vitamin E§
Intake of vitamin E — no./total no. (%) 359/831 (43.2) 354/834 (42.4)
Median — mg 8.7 8.8
Interquartile range — mg 5.9–14.5 5.7–15.1
Family history of preeclampsia — no./total no. (%)¶ 173/914 (18.9) 166/924 (18.0)
* Plus–minus values are means ±SD. Body-mass index is the weight in kilograms divided by the square of the height in 
meters.
† Data are from information obtained at the first antenatal visit in the first trimester.
‡ Race or ethnic group was self-reported.
§ Adequate dietary intake was defined as an intake at or above the recommended daily allowances in pregnancy (vitamin C, 
≥70 mg and vitamin E, ≥10 mg α-tocopherol equivalent)24 on the basis of dietary information.
¶ Family history is based on self-reports of preeclampsia in an immediate female relative such as mother, sister, or grand-
mother.
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tion of preeclampsia, severity of disease, use of 
magnesium sulfate, or induction of labor because 
of hypertension (Table 4). There were also no 
significant differences in other antenatal, intra-
partum or postnatal outcomes in self-reported side 
effects apart from a higher incidence of abdomi-
nal pain during late pregnancy in the vitamin 
group than the placebo group (7.9 percent vs. 
4.8 percent; relative risk, 1.63; 95 percent confi-
dence interval, 1.12 to 2.36).
Discussion
In this randomized, placebo-controlled trial, giv-
ing healthy nulliparous women supplements of 
1000 mg of vitamin C and 400 IU of vitamin E 
daily during pregnancy did not reduce their risk 
of preeclampsia, the risk of death or serious out-
comes in their infants, or the risk of intrauterine 
growth restriction. This finding contrasts with 
the findings in an earlier trial that supplementa-
tion with vitamins C and E was beneficial in 
women at high risk for preeclampsia.14 In our 
study, women in the vitamin group were more 
likely than those in the placebo group to be ad-
mitted antenatally with hypertension and to be 
treated with antihypertensive drugs. The cause of 
these unexpected adverse findings is unknown. 
They may be chance findings; however, such re-
search has suggested that antioxidants may pro-
mote DNA oxidation through an interaction be-
tween vitamin C and metal ions.25
For infants in our study, maternal vitamin 
supplementation was not associated with a reduc-









Fetal loss or death of infant 12 (1.3) 17 (1.8) 0.71 (0.34–1.48)
Early fetal death 3 (0.3) 7 (0.7) 0.43 (0.11–1.66)
Stillbirth 8 (0.9) 6 (0.6) 1.34 (0.47–3.86)
Neonatal death 1 (0.1) 4 (0.4) 0.25 (0.03–2.24)
Live birth 924 (98.8) 929 (98.6)
≥4 Days of tube feeding† 40 (4.3) 54 (5.8) 0.74 (0.50–1.11)
Severe IUGR (≥3rd percentile)† 23 (2.5) 36 (3.9) 0.64 (0.38–1.08)
≥2 Hr of hypotonia† 14 (1.5) 14 (1.5) 1.01 (0.48–2.10)
>4 Days of NICU care† 9 (1.0) 15 (1.6) 0.60 (0.27–1.37)
≥24 Hr of ventilation† 9 (1.0) 14 (1.5) 0.65 (0.28–1.49)
Stupor, decreased response to pain, or coma† 9 (1.0) 5 (0.5) 1.81 (0.61–5.38)
Seizure <24 hr of age or controlled by ≥2 drugs† 4 (0.4) 1 (0.1) 4.02 (0.45–35.9)
Apgar score <4 at 5 min† 3 (0.3) 3 (0.3) 1.01 (0.20–4.97)
Severe RDS†‡ 1 (0.1) 3 (0.3) 0.34 (0.03–3.22)
Chronic lung disease†§ 1 (0.1) 5 (0.5) 0.20 (0.02–1.72)
Grade 3 or 4 intraventricular hemorrhage† 1 (0.1) 1 (0.1) 1.01 (0.06–16.0)
Cystic periventricular leukomalacia† 0 1 (0.1) —
ROP requiring treatment† 0 1 (0.1) —
Necrotizing enterocolitis† 0 2 (0.2) —
* CI denotes confidence interval (unadjusted), IUGR intrauterine growth restriction, NICU neonatal intensive care unit, 
RDS respiratory distress syndrome, and ROP retinopathy of prematurity.
† The analysis included 924 live-born infants in the vitamin group and 929 live-born infants in the placebo group.
‡ Severe RDS was defined by a mean airway pressure of ≥10 mm Hg, a fraction of inspired oxygen of ≥0.80 cm of water, 
or both.
§ Chronic lung disease was defined as the need for oxygen at 36 weeks of postconceptual age for infants born at less 
than 32 weeks’ gestation or the need for oxygen on day 28 for infants born at 32 weeks’ gestation or more.
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Table 4. Secondary Maternal and Infant Outcomes.*
Outcome Vitamin Group Placebo Group  Relative Risk (95% CI)
Women
Total no. 935 942
Detection of preeclampsia
Median — wk 37.2 37.3
Interquartile range — wk 35.5–38.6 35.2–39.0
<34 wk — no. (%) 7 (0.7) 6 (0.6) 1.18 (0.40 to 3.48)
≥34 wk — no. (%) 49 (5.2) 41 (4.4) 1.20 (0.80 to 1.80)
Gestational hypertension — no. (%) 124 (13.3) 109 (11.6) 1.15 (0.90 to 1.46)
Severe gestational hypertension — no. (%) 29 (3.1) 21 (2.2) 1.39 (0.80 to 2.42)
Antenatal hospitalization for hypertension — no. (%) 49 (5.2) 32 (3.4) 1.54 (1.00 to 2.39)
Use of antihypertensive agents — no. (%) 43 (4.6) 26 (2.8) 1.67 (1.03 to 2.69)
Use of magnesium sulfate — no. (%) 12 (1.3) 7 (0.7) 1.73 (0.68 to 4.37)
Gestational diabetes — no. (%)† 35 (3.7) 33 (3.5) 1.07 (0.67 to 1.70)
Development of chorioamnionitis — no. (%)‡ 6 (0.6) 11 (1.2) 0.55 (0.20 to 1.48)
Induction of labor — no. (%)§ 311 (33.3) 283 (30.0) 1.11 (0.97 to 1.26)
For hypertension 70 (7.5) 51 (5.4) 1.38 (0.98 to 1.96)
Cesarean section — no. (%) 250 (26.7) 248 (26.3) 1.02 (0.87 to 1.18)
Elective 59 (6.3) 55 (5.8) 1.08 (0.76 to 1.54)
Emergency 191 (20.4) 193 (20.5) 1.00 (0.83 to 1.19)
Length of gestation — wk
Median 40.0 40.1
Interquartile range 39.0–41.0 39.0–41.0
Infants 
Total no.¶ 932 935
Preterm birth — no. (%)
<37 wk 64 (6.9) 63 (6.7) 1.02 (0.73 to 1.43)
<34 wk 20 (2.1) 19 (2.0) 1.06 (0.57 to 1.97)
<28 wk 6 (0.6) 6 (0.6) 1.00 (0.32 to 3.10)
Birth weight — g 3392±599 3386±584 6.0 (−48 to 59)
Length at birth — cm 50.4±3.2 50.3±3.2 0.0 (−0.3 to 0.3)
Head circumference — cm 34.5±1.9 34.4±2.0 0.1 (−0.1 to 0.3)
Respiratory distress syndrome — no. (%)∥ 2 (0.2) 12 (1.3) 0.17 (0.04 to 0.75)
Use of surfactant — no. (%)∥ 2 (0.2) 9 (1.0) 0.22 (0.05 to 1.03)
Use of mechanical ventilation — no. (%)∥ 13 (1.4) 23 (2.5) 0.57 (0.29 to 1.11)
* Plus–minus values are means ±SD. CI denotes confidence interval (unadjusted).
† Gestational diabetes was defined as a result of at least 7.8 mmol per liter on a two-hour oral glucose-tolerance test.
‡ The analysis included women requiring antibiotic treatment.
§ Indications for the induction of labor in the vitamin group and the placebo group, respectively, are past due dates, 
14.5 percent and 12.8 percent; hypertension, 7.5 percent and 5.4 percent; rupture of membranes, 5.6 percent and 4.9 
percent; severe intrauterine growth restriction, 1.1 and 1.6 percent; and other indications, 5.2 percent and 5.8 percent.
¶ The number of infants includes live births and stillbirths but not fetal losses before 20 weeks’ gestation.
∥ The analysis included 924 live-born infants in the vitamin group and 929 live-born infants in the placebo group.
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tion in the risk of a composite end point includ-
ing serious health outcomes or in the risk of in-
trauterine growth restriction. Although maternal 
supplementation was not associated with any over-
all benefits with respect to the primary infant 
outcomes, it was associated with a reduced risk 
of the respiratory distress syndrome and the use 
of surfactant. There was no significant difference 
in the rate of preterm birth between the two study 
groups. Oxidative stress has been implicated in 
diseases common among preterm infants, in-
cluding the respiratory distress syndrome and 
chronic lung disease.12,13 Maternal supplementa-
tion with antioxidant vitamins may increase the 
antioxidant status of at-risk infants and thus re-
duce the risk of diseases associated with oxida-
tive stress, independent of any effects on pre-
eclampsia and iatrogenic preterm birth. However, 
it remains possible that the isolated reductions in 
infant outcomes are due to chance, given that sta-
tistical adjustment was not made for multiple com-
parisons in the analyses of secondary outcomes.
Adherence to the trial medications in our 
study was similar to that in other supplementa-
tion trials involving nulliparous women.23,26 We 
found no significant differences in adherence be-
tween the two groups. The doses we used are 
similar to those of two previous trials of supple-
mentation with vitamins C and E.14,15 Doses of 
vitamin C of 1000 mg per day,27 which is the 
dose we used, result in plasma saturation. For vita-
min E, doses of 400 IU per day have been shown 
to prevent low-density lipoprotein oxidation,28 
with limited evidence that higher doses (above 
400 IU per day) are more effective. It is therefore 
unlikely that higher doses of these vitamins 
would have reduced the rate of preeclampsia.
The group receiving vitamin supplementation 
had a higher rate of elevated aminotransferase 
levels than did the placebo group. No increased 









Death or serious maternal outcome 94 (10.1) 73 (7.7) 1.30 (0.97–1.74)
Preterm PROM 30 (3.2) 23 (2.4) 1.31 (0.77–2.25)
Major postpartum hemorrhage† 27 (2.9) 28 (3.0) 0.97 (0.58–1.64)
Abnormal liver function‡ 21 (2.2) 10 (1.1) 2.12 (1.00–4.47)
Postpartum pyrexia§ 11 (1.2) 7 (0.7) 1.58 (0.62–4.07)
Renal insufficiency¶ 9 (1.0) 5 (0.5) 1.81 (0.61–5.39)
Pneumonia 3 (0.3) 2 (0.2) 1.51 (0.25–9.02)
Coagulopathy 3 (0.3) 3 (0.3) 1.01 (0.20–4.98)
Thrombocytopenia 3 (0.3) 1 (0.1) 3.02 (0.31–29.0)
Placental abruption∥ 3 (0.3) 1 (0.1) 3.02 (0.31–29.0)
Oliguria** 2 (0.2) 1 (0.1) 2.01 (0.18–22.2)
Pulmonary edema 1 (0.1) 1 (0.1) 1.01 (0.06–16.1)
Deep-vein thrombosis 0 1 (0.1) —
Pulmonary embolus 0 1 (0.1) —
* There were no cases of eclampsia, stroke, death, respiratory distress syndrome, cardiac arrest, or respiratory arrest in 
either study group. CI denotes confidence interval (unadjusted), and PROM prelabor rupture of membranes.
† Major postpartum hemorrhage was defined by a blood loss of ≥1500 ml or use of blood transfusion.
‡ Abnormal liver function was defined by levels of aspartate aminotransferase or alanine aminotransferase ≥50 IU per li-
ter. Data are available only for a subgroup of women for whom testing was considered clinically indicated and whose 
test results were abnormal.
§ Postpartum pyrexia was defined as a temperature of ≥38.5°C on two occasions >24 hours apart.
¶ Renal insufficiency was defined by a serum creatinine level ≥0.09 mmol per liter.
∥ Placental abruption was defined as abdominal pain and bleeding before birth associated with a retroplacental clot at 
delivery.
** Oliguria was defined by the output of <30 ml of urine per hour for ≥6 hours.
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risk of abnormal liver function has been reported 
in previous randomized trials of supplementation 
with vitamins C and E in pregnancy29 or in trials 
of high-dose supplementation outside pregnan-
cy.30 In our study, liver function was assessed 
only in women considered to have clinical indi-
cations for testing, and therefore, the results of 
testing are known only for a subgroup of women. 
This assessment was one of multiple comparisons 
performed, and the results may be due to chance; 
other studies of supplementation with vitamins 
C and E in pregnancy should assess liver-func-
tion tests.
The majority of the women we studied had a 
baseline dietary intake of vitamins C and E above 
the recommended daily amount.24 Thus, the re-
sults cannot be generalized to women with low 
dietary intakes of antioxidants. An ongoing trial 
is assessing whether antioxidants are beneficial 
in such women.31 Ongoing trials are also assess-
ing whether antioxidant supplementation is ben-
eficial for nulliparous women32,33 and for women 
considered to be at increased risk for preeclamp-
sia, including women with diabetes34 and those 
who had preeclampsia during a previous preg-
nancy.31,33,35
Our results indicate that daily supplementa-
tion with 1000 mg of vitamin C and 400 IU of 
vitamin E does not reduce the risk of preeclamp-
sia in nulliparous pregnant women or the risk of 
serious perinatal complications or poor intra-
uterine growth in their infants. Our results do 
not support routine supplementation with vita-
mins C and E during pregnancy to prevent pre-
eclampsia or other adverse perinatal outcomes in 
nulliparous women.
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